All In Biotech

Drug Trial Radar · NCT02669017

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Last checked: Nov 20, 2026Latest source record: May 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

183

Actual

Start

Mar 2016

Primary completion

Feb 21, 2019

Study completion Feb 21, 2019

Sponsor

Lead sponsor
ADC Therapeutics S.A.Industry
Sponsor type
Industry
First posted
Jan 29, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates ADCT-402 in participants with Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL). Participants will participate in a dose escalation phase (Part 1) and dose expansion (Part 2). In Part 2, participants will receive the dose level identified in Part 1.

Conditions

  • Non-Hodgkin Lymphoma
  • Burkitt's Lymphoma
  • Chronic Lymphocytic Leukemia
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Follicular
  • Lymphoma, Mantle-Cell
  • Lymphoma, Marginal Zone
  • Waldenstrom Macroglobulinemia
  • Primary Mediastinal B-cell Lymphoma

Interventions

  • ADCT-402Drug

    intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)Time frame: Q3W schedule: Day 1 to End of Cycle 1 (3 weeks); Q6W schedule: Day 1 to End of Cycle 1 (6 weeks)
  2. Recommended Dose of ADCT-402 for Part 2Time frame: Q3W schedule: Day 1 to End of Cycle 1 (3 weeks); Q6W schedule: Day 1 to End of Cycle 1 (6 weeks)
  3. Number of Participants Reporting at Least One Treatment Emergent Adverse Event (TEAE)Time frame: Day 1 to End of Study (a maximum of 18 months)
  4. Number of Participants Reporting at Least One Treatment Emergent Serious Adverse Event (SAE)Time frame: Day 1 to End of Study (a maximum of 18 months)

Locations

11 sites in 3 countries. Site status is shown where the registry gives one.

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Blood and Marrow Transplant Group of Georgia

    Atlanta, Georgia

  • Washington University School of Medicine

    St Louis, Missouri

  • Columbia University Medical Center Herbert Irving Pavilion

    New York, New York

  • University Hospitals of Cleveland

    Cleveland, Ohio

  • Greenville Health System, Institute for Translational Oncology Research, Clinical Research Unit

    Greenville, South Carolina

  • Froedtert Hospital & the Medical College of Wisconsin

    Milwaukee, Wisconsin

  • U.O Oncologia e Ematologia - Istituto Clinico Humanitas

    Milan, Italy

  • University College London Hospitals

    London, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.